A plain-language guide
PHP Biotech is building a tiny protein — about one-tenth the size of a typical antibody — designed to walk into a tumor cell and restart a broken safety switch called p53. This page explains that idea without the jargon, and flags the words we still need.
Inside a healthy cell, a protein named p53 can tell that cell to stop dividing — or to die — if its DNA is too damaged to fix. Many aggressive cancers mute that order. PHP’s lead candidate, PHP53-nb, is a very small antibody-like protein meant to enter those tumor cells and help turn the order back on. It has shown promise in laboratory dishes and animal models. It has not been given to people.
That last sentence matters more than the rest. Laboratory success is not a medicine. Nothing on this website is medical advice, and PHP53-nb is not FDA-approved.
The problem
Think of p53 as the building’s fire system: it notices damage and can shut the floor down, or empty it, before the fire spreads. The gene that makes p53 is called TP53. When TP53 is mutated, the alarm is still on the wall — it just doesn’t ring.
That is not a rare glitch. Roughly half of all human cancers carry a TP53 mutation. In some of the meanest tumors the share is higher still. Drugmakers have tried for decades to restart p53. It is a famous, stubborn target, which is why a new way in is worth explaining carefully.
Where we start
Many breast cancers can be treated by aiming at one of three “handles” on the cell: estrogen receptors, progesterone receptors, or HER2. Triple-negative breast cancer (TNBC) has none of those three, so the usual targeted drugs have little to grab. TNBC also often carries TP53 mutations. That combination — few handles, a broken p53 switch — is why PHP is starting there, with other hard tumors such as pancreatic and ovarian cancer in the wider preclinical view.
Two pieces, one molecule
The idea is not one invention. It is two, fused so they cannot come apart in the bloodstream.
The message · 3-NAntC
A peptide is a tiny stretch of protein — more like a sentence than a book. 3-NAntC is a lab-made fragment inspired by a piece of rattlesnake venom that can stress certain breast-cancer cells. In a 2024 peer-reviewed paper, it lowered the survival of an aggressive TNBC cell line while leaving ordinary breast cells mostly unharmed. The catch: peptides this small are usually shredded in blood, the way a paper note ruins in the rain.
The case · GEN01-AD
A nanobody is a miniature antibody. Camels and llamas make a naturally small version; PHP’s is engineered and humanized. At about 17 kilodaltons it is roughly one-tenth the bulk of the monoclonal antibodies used in many cancer clinics (~150 kDa). The peptide is not taped onto this case with a chemical linker. It is written into the nanobody’s own sequence, so manufacturing is one protein, not a glue job.
Put together, that single protein is called PHP53-nb — “nb” for nanobody. The platform underneath, which could in principle carry other messages later, is GEN01-AD.
This is the company’s working model, based on laboratory studies. It is a map, not a guarantee of what will happen in a person.
1
The nanobody is built to prefer a marker that shows up more often on certain cancer cells than on ordinary tissue — a bit like a package addressed to one house, not every house on the street.
2
Instead of sitting on the surface, it is swallowed into the cell in a small bubble. Scientists call this endocytosis. For this program, getting inside is the whole point.
3
The 3-NAntC peptide is written into the nanobody’s own gene — not glued on later. Once the bubble opens in the cell’s interior (the cytoplasm), the payload is already there.
4
Inside, the construct stresses the cell’s recycling and protein-folding machinery. In the company’s model, that pressure helps restart p53, the protein that is supposed to order a damaged cell to die.
5
If the order goes through, the cell’s energy factories (mitochondria) fail and the cell undergoes apoptosis — a quiet, programmed death rather than a messy explosion. In published peptide work, ordinary breast cells were largely spared at the same dose.
A few terms are worth keeping. Each one is also in the glossary.
If you want the technical version, the primary paper, or a conversation with the company, start here.
Reviewed against the company’s public descriptions and the open-access 3-NAntC paper (Bezerra & Motti, Molecules 2024, PMID 38611925). Last reviewed August 2026.